Optimal immunosuppressive therapy after living liver transplantation in adult
| Project/Area Number |
26461929
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
Ogata Satoshi 東京女子医科大学, 医学部, 助教 (40444583)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
江川 裕人 東京女子医科大学, 医学部, 教授 (40293865)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 生体肝移植 / 免疫モニタリング / 免疫抑制剤 / 過小グラフト |
|---|
| Outline of Final Research Achievements |
Infection or rejection following living liver transplantation often causes critical liver dysfunction with insufficient hepatic capacity in the early postoperative period. Therefore, immunosuppressive induction therapy in living liver transplantation requires more strict postoperative management than whole liver transplantation. We attempted to reduce complications by using immunosuppressive induction therapy with tacrolimus, methylprednisolone and MMF after liver transplantation, in particular using lower dose tacrolimus. As a result, the incidence of rejection was acceptable, establishing a protocol that is less than that of renal dysfunction, postoperative glucose tolerance, which is a side effect of calcineurin inhibitor.
|
Report
(4 results)
Research Products
(11 results)
